Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Oncology Institute (TOI) Liabilities and Shareholders Equity (2020 - 2025)

Oncology Institute (TOI) has disclosed Liabilities and Shareholders Equity for 6 consecutive years, with $163.6 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Liabilities and Shareholders Equity fell 8.69% year-over-year to $163.6 million, compared with a TTM value of $660.1 million through Sep 2025, down 14.55%, and an annual FY2024 reading of $172.7 million, down 17.46% over the prior year.
  • Liabilities and Shareholders Equity was $163.6 million for Q3 2025 at Oncology Institute, up from $159.8 million in the prior quarter.
  • Across five years, Liabilities and Shareholders Equity topped out at $283.8 million in Q3 2022 and bottomed at $159.8 million in Q2 2025.
  • Average Liabilities and Shareholders Equity over 5 years is $208.0 million, with a median of $206.5 million recorded in 2022.
  • The sharpest move saw Liabilities and Shareholders Equity soared 209.7% in 2021, then dropped 23.06% in 2023.
  • Year by year, Liabilities and Shareholders Equity stood at $203.4 million in 2021, then grew by 28.62% to $261.7 million in 2022, then dropped by 20.04% to $209.2 million in 2023, then decreased by 17.46% to $172.7 million in 2024, then fell by 5.27% to $163.6 million in 2025.
  • Business Quant data shows Liabilities and Shareholders Equity for TOI at $163.6 million in Q3 2025, $159.8 million in Q2 2025, and $164.0 million in Q1 2025.